0001628280-26-026642
SEC filingVanda Pharmaceuticals Inc. expanded its Board of Directors to seven members and appointed Dr. Charles C. Duncan as an independent director effective April 22, 2026, with a compensation package including an initial $390,000 restricted stock unit award and a $50,000 annual fee.
Vanda Pharmaceuticals has strengthened its governance by adding Dr. Charles Duncan, a seasoned biotechnology analyst with nearly three decades of industry experience, to its board. His appointment increases board independence, with six of seven directors now classified as independent. Dr. Duncan's compensation aligns with standard director packages, featuring equity-based incentives that vest over time and include change-of-control acceleration provisions. His background in neurology and psychiatry research complements Vanda's focus on CNS disorders, though the filing contains no specific strategic initiatives tied to his appointment. The company emphasizes his expected contribution to board discussions as Vanda advances its clinical pipeline, including recently approved products NEREUS and BYSANTI.